Filing Flows › Integrated Biopharma (INBP) › Capital expenditures
Integrated Biopharma (INBP) capital expenditures by quarter
Integrated Biopharma's capital expenditures were $24K in Q2 FY26 (second quarter fiscal 2026), -86% from Q1 FY26. Over the last 4 quarters it ranged from $24K (Q2 FY26) to $173K (Q1 FY26).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 FY26 | $24K | -86% | -17% |
| Q1 FY26 | $173K | +49% | — |
| Q3 FY25 | $116K | +300% | — |
| Q2 FY25 | $29K | — | — |
Q2 FY26 at a glance
Integrated Biopharma, Q2 FY26: revenue $11.3M (-11% year over year), operating margin -8.1%, net loss $762K, operating cash flow $617K. The chart follows the revenue to costs, profit and cash.
Questions
What is Integrated Biopharma's capital expenditures?
Integrated Biopharma's capital expenditures were $24K in Q2 FY26 (second quarter fiscal 2026), -86% from Q1 FY26.
How has Integrated Biopharma's capital expenditures changed?
Over the last 4 quarters it ranged from $24K (Q2 FY26) to $173K (Q1 FY26).